Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats

被引:26
作者
Uto, Yoshikazu [1 ]
Ogata, Tsuneaki [2 ]
Kiyotsuka, Yohei [1 ]
Ueno, Yuko [1 ]
Miyazawa, Yuriko [1 ]
Kurata, Hitoshi [1 ]
Deguchi, Tsuneo [3 ]
Watanabe, Nobuaki [3 ]
Konishi, Masahiro [4 ]
Okuyama, Ryo [4 ]
Kurikawa, Nobuya [4 ]
Takagi, Toshiyuki [5 ]
Wakimoto, Satoko [4 ]
Ohsumi, Jun [4 ]
机构
[1] Daiichi Sankyo Co Ltd, Med Chem Res Labs 1, Shinagawa Ku, Tokyo 1408710, Japan
[2] Daiichi Sankyo Co Ltd, Global Project Management Dept, Shinagawa Ku, Tokyo 1408710, Japan
[3] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[4] Daiichi Sankyo Co Ltd, Biol Res Labs 2, Shinagawa Ku, Tokyo 1408710, Japan
[5] Daiichi Sankyo Co Ltd, Clin Dev Dept 1, Shinagawa Ku, Tokyo 1408710, Japan
关键词
Stearoyl-CoA desaturase (SCD); Benzoylpiperidine; Zucker fatty rat; POTENT INHIBITORS; SCD INHIBITORS; DISCOVERY; LEPTIN; GENE; MICE; DISRUPTION; OBESITY; TARGET; ESTERS;
D O I
10.1016/j.bmcl.2009.10.101
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Starting from a known piperazine-based SCD-1 inhibitor, we obtained more potent benzoylpiperidine analogs. Optimization of the structure of the benzoylpiperidine-based SCD-1 inhibitors resulted in the identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-yl-ethyl)amide (24) which showed strong inhibitory activity against both human and murine SCD-1. In addition, this compound exhibited good oral bioavailability and demonstrated plasma triglyceride lowering effects in Zucker fatty rats in a dose-dependent manner after a 7-day oral administration (qd). (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:341 / 345
页数:5
相关论文
共 31 条
[1]   Bromine-magnesium-exchange as a general tool for the preparation of polyfunctional aryl and heteroaryl magnesium-reagents [J].
Abarbri, M ;
Dehmel, F ;
Knochel, P .
TETRAHEDRON LETTERS, 1999, 40 (42) :7449-7453
[2]  
ABREO M, 2005, Patent No. 2005011655
[3]   ATHEROGENESIS IN 2 STRAINS OF OBESE RATS - THE FATTY ZUCKER AND LA/N-CORPULENT [J].
AMY, RM ;
DOLPHIN, PJ ;
PEDERSON, RA ;
RUSSELL, JC .
ATHEROSCLEROSIS, 1988, 69 (2-3) :199-209
[4]   Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia [J].
Attie, AD ;
Krauss, RM ;
Gray-Keller, MP ;
Brownlie, A ;
Miyazaki, M ;
Kastelein, JJ ;
Lusis, AJ ;
Stalenhoef, AFH ;
Stoehr, JP ;
Hayden, MR ;
Ntambi, JM .
JOURNAL OF LIPID RESEARCH, 2002, 43 (11) :1899-1907
[5]  
BLACK C, 2007, Patent No. 2007009236
[6]   Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr) [J].
Chua, SC ;
White, DW ;
WuPeng, XS ;
Liu, SM ;
Okada, N ;
Kershaw, EE ;
Chung, WK ;
PowerKehoe, L ;
Chua, M ;
Tartaglia, LA ;
Leibel, RL .
DIABETES, 1996, 45 (08) :1141-1143
[7]   Stearoyl-CoA desaturase as a new drug target for obesity treatment [J].
Dobrzyn, A ;
Ntambi, JM .
OBESITY REVIEWS, 2005, 6 (02) :169-174
[8]   Inhibition of stearoyl-CoA desaturase by cyclic amine derivatives [J].
Dobrzyn, Agnieszka ;
Dobrzyn, Pawel .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (04) :457-460
[9]   Stearoyl-CoA desaturase: A new therapeutic target of liver steatosis [J].
Dobrzyn, Pawel ;
Dobrzyn, Agnieszka .
DRUG DEVELOPMENT RESEARCH, 2006, 67 (08) :643-650
[10]   Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism [J].
Flowers, Matthew T. ;
Ntambi, James M. .
CURRENT OPINION IN LIPIDOLOGY, 2008, 19 (03) :248-256